CMS Threatens to Suspend Elevance Health's MA-PD Enrollment Over Risk-Adjustment Issues
ELV is trading near its 52-week low of $273.71 (13% above the low) on elevated volume (2.7× avg).
Summary
Elevance Health has been notified by the Centers for Medicare & Medicaid Services (CMS) of its intent to suspend new enrollment in Medicare Advantage-Prescription Drug (MA-PD) plans and restrict certain beneficiary communications, effective March 31, 2026, if issues are not resolved. The proposed sanctions stem from alleged noncompliance with Medicare Advantage risk adjustment data submissions for services provided before April 3, 2023. While Elevance states it revised practices in April 2023 and is engaging with CMS, the potential suspension of new MA-PD enrollment is a material negative development for the company, as Medicare Advantage is a crucial growth segment. This regulatory action could hinder future revenue growth and market share, adding to the company's complex regulatory landscape noted in its recent 10-K. Investors will be watching for updates on Elevance's discussions with CMS and the potential resolution of these issues.
At the time of this announcement, ELV was trading at $310.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $70.6B. The 52-week trading range was $273.71 to $458.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Unknown.